Browse News
Filter News
Found 1,134 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023
3/27/2024
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines and vaccines, today announced its financial results for the full year ended December 31, 2023, along with a corporate update.
-
Synthekine Announces U.S. FDA Clearance of IND Application for CD19 CAR-T and Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, for Treatment of Lupus Without Lymphodepletion
3/26/2024
Synthekine Inc., an engineered cytokine therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to evaluate SYNCAR-001 + STK-009, its orthogonal IL-2 and CD19 CAR-T combination therapy, in patients with non-renal systemic lupus erythematosus (SLE) and lupus nephritis (LN), without the use of any lymphodepletion.
-
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
3/26/2024
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) today reported its business highlights and financial results for the full year ended December 31, 2023.
-
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
3/25/2024
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2023, as well as corporate and clinical highlights.
-
Immunotherapy Drugs Industry is Rapidly Growing with CAGR of 18.03%
3/22/2024
According to Vision Research Reports, the global immunotherapy drugs market size was valued at USD 239.21 billion in 2023 and it is projected to hit around USD 1,063.44 billion by 2032, growing at a CAGR of 18.03% from 2023 to 2032.
-
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
3/22/2024
Equillium, Inc. today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference, and the LD Micro Invitational Conference.
-
HI-Bio Receives FDA Orphan Drug Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection (AMR) in Kidney Transplant Recipients
3/21/2024
Human Immunology Biosciences (HI-Bio™) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for felzartamab for the treatment of antibody-mediated rejection (AMR) in kidney transplant recipients.
-
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
3/21/2024
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the fourth quarter and year ended December 31, 2023.
-
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
3/20/2024
Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today reported its business highlights and financial results for the fourth quarter and year ended December 31, 2023.
-
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
3/19/2024
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2023.
-
Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results
3/18/2024
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported full year 2023 financial results and company highlights for the fourth quarter ended December 31, 2023.
-
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
3/14/2024
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.
-
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
3/8/2024
Kyverna Therapeutics, Inc. announced the signature of a collaboration agreement with Stanford University to allow the use of KYV-101, an investigational, anti-CD19 CAR T-cell therapy in an open label, phase 1 investigator-initiated trial in nine to twelve adult subjects with non-relapsing and progressive forms of multiple sclerosis.
-
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
2/29/2024
Atara Biotherapeutics, Inc. today announced the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for ATA3219.
-
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
2/29/2024
Aurinia Pharmaceuticals Inc. today announced that Canadian securities regulators have granted exemptive relief for the Company’s share repurchase program, authorizing the Company to purchase up to 15 percent of its issued and outstanding shares in any 12-month period for up to 36 months, including under the Current Program.
-
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
2/29/2024
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2023.
-
ImmPACT Bio Awarded $8 Million CIRM Grant for Phase 1b/2 Development of IMPT-514, a CD19/CD20 Bispecific CAR T-Cell Therapy for Refractory Lupus Nephritis and Systemic Lupus Erythematosus
2/28/2024
ImmPACT Bio Awarded $8 Million CIRM Grant for Phase 1b/2 Development of IMPT-514, a CD19/CD20 Bispecific CAR T-Cell Therapy for Refractory Lupus Nephritis and Systemic Lupus Erythematosus.
-
Lupus Research Alliance Announces Recipients of the Lupus Mechanisms and Targets Award
2/28/2024
The Lupus Research Alliance is pleased to announce the recent recipients of the Lupus Mechanisms and Targets Award, whose research will investigate molecular pathways or targets that will lead to new or improved therapies for individuals with systemic lupus erythematosus.
-
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
2/28/2024
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate on the Cardiorenal Corporate Panel at the TD Cowen 44th Annual Health Care Conference.